http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pyloric Gland Adenoma in Lynch Syndrome
Lee, Seung Eun,Kang, So Young,Cho, Junhun,Lee, Boram,Chang, Dong Kyung,Woo, Hyein,Kim, Jong Won,Park, Ha Young,Do, In Gu,Kim, Young Eun,Kushima, Ryoji,Lauwers, Gregory Y.,Park, Cheol Keun,Kim, Kyoung Raven Press 2014 The American journal of surgical pathology Vol.38 No.6
<P>The prevalence of gastric cancer associated with Lynch syndrome (LS) is highly variable, and the underlying histologic pathway or molecular mechanisms remain unclear. From 1995 to 2012, 15 patients had been treated for both gastric and colonic adenocarcinomas and diagnosed as LS. In all cases, pathologic review, immunohistochemical analysis for mismatch-repair proteins, and microsatellite instability (MSI) tests were performed. To confirm LS, germline mutation tests and multiplex ligation-dependent probe amplification were performed. All gastric and colonic carcinomas were MSI-high and lost expressions of MLH1/PMS2 in 11 (73%) cases and MSH2/MSH6 in 4 (27%) cases. Remarkably, in a patient with LS and germline mutation of <I>MLH1</I> gene, pyloric gland adenoma (PGA) transformed to adenocarcinoma during follow-up. In 2 additional cases, PGA was found adjacent to advanced gastric cancers. All PGAs in LS patients were MSI-high and lost expression of mismatch-repair proteins (MLH1/PMS2 in 2 cases and MSH2/MSH6 in 1 case), whereas none of the 14 sporadic PGAs was MSI-high or had lost expression of mismatch-repair proteins. On the basis of these observations, although very rare, we suggest the possibility that PGA may be a precursor lesion to gastric adenocarcinoma in LS and that the mismatch-repair deficient pathway of carcinogenesis is involved early in the gastric carcinogenesis pathway.</P>
Lee, Kyo Won,Kim, Tae Min,Kim, Kyeong Sik,Lee, Seunghwan,Cho, Junhun,Park, Jae Berm,Kwon, Ghee Young,Kim, Sung Joo Hindawi 2018 Journal of diabetes research Vol.2018 No.-
<P>Clinically, acute kidney injury (AKI) episodes in diabetes mellitus (DM) patients are associated with a cumulative risk of developing end-stage renal disease. In this study, we asked whether the severity of AKI induced by renal ischemia-reperfusion injury (IRI) is more prominent in DM than in non-DM control using a cynomolgus monkey (<I>Macaca fascicularis)</I> model. We also investigated whether human bone marrow-derived mesenchymal stem cells (hBM-MSCs) infused via the renal artery could ameliorate renal IRI in DM monkeys. The experimental data, including mortality rate, histologic findings, and urinary albumin secretion indicate that the severity of AKI was greater in DM monkeys than in control animals. Moreover, histological findings and qRT-PCR analysis of <I>Ngal</I> mRNA in renal biopsy tissue showed that hBM-MSC promoted the recovery of tubular damage caused by AKI. Serum analysis also revealed that the level of albumin and ALT was increased 24 and 48 hours after AKI, respectively, suggesting that AKI induced acute liver injury. We suggest that this nonhuman primate model could provide essential information about the renal and nonrenal impairment related to DM and help determine the clinical usefulness of MSCs in AKI.</P>
디지로그 북 저작을 위한 펜형 햅틱 사용자인터페이스의 개발
이준훈(Junhun Lee),하태진(Taejin Ha),류제하(Jeha Ryu),우운택(Woontak Woo) 한국HCI학회 2009 한국HCI학회 학술대회 Vol.2009 No.2
차세대 출판문인 디지로그 북은 기존 서적과 디지털콘텐츠를 통합하여 사용자에게 아날로그적 감성과 디지털오감을 제공한다. 이러한 디지로그 북을 제작하기 위해 디지로그 북의 저작도구에 대한 연구가 진행 중이며, 본 논문에서는 디지로그 북에 사용될 콘텐츠를 저작하는 활동에서 시각과 청각에만 의존한 작업을 보다 실감 있도록 하기 위해 펜형 햅틱 사용자인터페이스를 개발하고자 하였다. 햅틱 사용자인터페이스는 디지로그 북을 저작하는 작업에서 3차원 작업공간에서 공간상에 배치되는 3차원 객체를 이동, 회전, 크기 변경 및 메뉴선택 버튼의 클릭등과 같은 다양한 작업에서 각 작업을 보다 실감 있게 하기 위한 진동 햅틱 효과를 사용자에게 제공한다. 본 연구에서는 이러한 디지로그 북의 저작 환경에 적합한 사용자인터페이스의 외형, 회로 설계, 진동패턴의 설계/내장 및 저작시스템과의 연동을 위한 프로토콜을 정의하고 이렇게 개발된 햅틱 사용자인터페이스를 사용하여 사용자평가를 간단히 실시하였다. 디지로그 북 저작 작업에서 이렇게 개발된 햅틱 인터페이스의 촉각 효과를 시청각정보와 함께 사용함으로써 디지로 그 북 저작 작업을 보다 효과적으로 할 수 있기를 기대한다. Digilog Book, the next generation publication material, supplies digitalized contents on an analog book by integrating digital contents into existing analog books. There are some studies related to authoring tools which are to authorize, and publish some books which provide digital contents by using VR or AR techniques. In this paper, a pen-type haptic user interface for Digilog Book authoring tool has been introduced. This haptic user interface is developed for more realistic and more effective authoring tasks. This haptic interface provides haptic effects for authoring tasks which are including translation, rotation, scaling, and menu selection. In this research, we designed a body, control circuits, vibration haptic patterns for haptic user interface, and a protocol for between haptic user interface and Digilog Book main control system. Also a simple user study has been done with a developed haptic user interface.
Bridging genomics and phenomics of gastric carcinoma
Cho, Junhun,Ahn, Soomin,Son, Dae‐,Soon,Kim, Nayoung KD,Lee, Ki‐,Wook,Kim, Seungtae,Lee, Jeeyun,Park, Se Hoon,Park, Joon Oh,Kang, Won Ki,An, Ji Yeong,Choi, Min Gew,Lee, Jun‐,Ho,Sohn, Alan R. Liss, Inc 2019 International journal of cancer Vol.145 No.9
<P>Genetic alterations are the starting point leading to numerous changes in clinical and pathologic features (phenotypes) of individual cancers; however, their inter‐relationships in gastric cancers (GC) are unclear. We performed massive parallel sequencing of 381 cancer‐related genes and compared the results with clinical and pathologic findings in 330 GC. High tumor mutation burden (TMB) accounted for 11% of GC (<I>n</I> = 37) and all 19 MSI‐H GCs were high TMB. High TMB was significantly more frequent in intestinal‐type by Lauren, tumor with higher host cellular immune response, earlier AJCC stage and favorable prognosis. The most significantly mutated genes were <I>TP53</I> (54%), <I>ARID1A</I> (23%), <I>CDH1</I> (22%), <I>PIK3CA</I> (12%), <I>RNF43</I> (10%) and <I>KRAS</I> (9%). For receptor tyrosine kinases, amplifications detected by immunohistochemistry were higher than sequencing (HER2, 9.1% <I>vs</I>. 5.8%; EGFR, 11.2% <I>vs</I>. 6.1%; FGFR2, 4.6% <I>vs</I>. 3.9%, c‐MET, 3.4% <I>vs</I>. 0.9%). PTEN protein loss (22%) correlated well with underlying <I>PTEN</I> alterations while ATM loss (27%) was not significantly correlated with genetic alterations of <I>ATM</I>. p53 protein expression predicted alterations of <I>TP53</I> with high sensitivity (97.8%) and low (15.9%) specificity. The poorly cohesive histology/<I>CDH1</I>‐mutant GC subgroup showed the worst survival (<I>p</I> < 0.001). PD‐L1 expression was significantly associated with MSI‐H, MLH1 loss, ATM loss, MET positivity, higher host immune response, and genetic alterations of <I>ARID1A</I>, <I>BRD3</I>, <I>PIK3CA</I>, <I>KRAS</I>, <I>MAP3K13</I>, <I>CDH2, PTEN</I> and <I>ESR1</I>. The merged clinical, pathology and genomics of GC provide a better understanding of GC and new insights into the treatment of GC.</P>
( Se Jin Oh ),( Jongeun Lee ),( Ji-hye Park ),( Jong Hee Lee ),( Junhun Cho ),( Young-hyeh Ko ),( Dongyoun Lee ) 대한피부과학회 2021 Annals of Dermatology Vol.33 No.3
Background: Hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) is rare Epstein-Barr virus (EBV)-associated disease. The classic form of HVLPD is a self-resolving disease, whereas the systemic form can progress to malignant lymphoma, resulting in fatal outcomes. However, the prognostic factors remain unclear. Objective: This study aimed to evaluate the clinical characteristics of HVLPD and the association between whole blood EBV DNA and clinical outcomes. Methods: We retrospectively reviewed our 25-year experience involving 11 patients with HVLPD from a single tertiary center in South Korea and evaluated the clinical characteristics of HVLPD and the correlation between whole blood EBV DNA and clinical outcomes. Results: Of the total 11 patients, 54.5% (6/11) manifested classic HVLPD that resolved with conservative treatment, while 45.5% (5/11) patients had systemic HVLPD, four of whom died of progressive disease or hemophagocytic syndrome. Five patients with systemic HVLPD manifested severe skin lesions such as prominent facial edema, deep ulcers and necrotic skin lesions involving sun-protected areas. Median EBV DNA levels at initial diagnosis were higher in three dead patients than in those alive (2,290 vs. 186.62 copies/μl). Conclusion: When EBV DNA levels were high, patients showed severe skin lesions and when EBV DNA levels were low, skin lesions tended to improve. Thus, patients with high EBV DNA levels showed an increased risk of severe skin lesions and disease progression. (Ann Dermatol 33(3) 222∼227, 2021)
A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
Yong-Pyo Lee,Ye Ji Jung,Junhun Cho,Young Hyeh Ko,Won Seog Kim,Seok Jin Kim,Sang Eun Yoon 대한혈액학회 2023 Blood Research Vol.58 No.4
Background While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL (RR-MCL). This study investigated real-world treatment outcomes of ibrutinib in patients with RR-MCL. Methods A single-center retrospective analysis investigated clinical characteristics and survival outcomes of patients with RR-MCL, treated with ibrutinib. Results Forty-two patients were included, with 16 received rituximab and bendamustine, and 26 receiving anthracycline-based regimens as front-line treatment. During a median follow- up of 46.0 months, the response rate to ibrutinib was 69%, with 12 CRs and 8 partial responses. Disease progression (54.8%) and adverse events (11.9%) were the primary reasons for discontinuation. Median progression-free survival (PFS) and overall survival (OS) were approximately 16.4 and 50.1 months, respectively. Patients older than 70 years (P =0.044 and P=0.006), those with splenomegaly (P =0.022 and P =0.006), and those with a high-risk simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) (P <0.001 and P <0.001) exhibited siginificantly inferior PFS and OS. Notably, patients with a high-risk sMIPI relapsed earlier. Post-ibrutinib treatment yilded an OS of 12.2 months, while clinical trial participants demonstrated superior survival compared to those receiving chemotherapy alone. Conclusion This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.